Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00610506 · ClinicalTrials.gov registry record · Phase 3
Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features
A Phase 3 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT00610506 is a Phase 3 study that has completed, run by Duke University. The registered enrollment target is 15 participants.
The verdict
NCT00610506, a Phase 3 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram in major depression with atypical features. Study hypothesis and objectives. This study is proposed as an open-label study to gather pilot data to examine whether escitalopram has clinical utility in the treatment of major depression with atypical features. Because of the exploratory nature of the design, no specific study hypotheses can be generated regarding efficacy of the drug. Our primary hypothesis is that the effect size of escitalopram in atypical depression will be similar to the effect size of escitalopram in major depression, its FDA approved indication.
Interventions
- DRUG Escitalopram
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00610506
The ClinicalTrials.gov registry entry for NCT00610506 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Escitalopram is the first listed.
NCT00610506 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00610506 about?
NCT00610506 is a clinical study titled "Escitalopram (Lexapro®) In Patients With Major Depression With Atypical Features". Aims of Study: The aims of this study are 1) to examine the clinical utility of escitalopram in patients with major depression with atypical features; 2) to evaluate the tolerability of escitalopram in major depression with atypical features. Study hypothesis and objectives. This study is proposed...
What is the current status of trial NCT00610506?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2005-10. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00610506?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00610506?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.